3Z uses advanced disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Nýsköpunar... | nyskopun.i... |
Mentions in press and media 13
| Date | Title | Description |
| 25.02.2025 | 3Z Pharmaceuticals Unveils New Insights into ADHD Treatment Mechanisms | In the realm of neurodevelopmental disorders, Attention Deficit Hyperactivity Disorder (ADHD) stands out as a pervasive challenge. Its complexity often leaves patients and healthcare providers navigating a fog of uncertainty. However, a rec... |
| 24.02.2025 | 3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics | 3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics Mon, Feb 24, 2025 16:06 CET Report this content REYKJAVIK, Iceland, 24 February 2025 – 3Z Pharmaceuticals, a CNS-focused therapeutic developme... |
| 24.02.2025 | 3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics | REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, ... |
| 18.02.2025 | Amlodipine: A New Hope for ADHD Treatment | In a world where attention deficit hyperactivity disorder (ADHD) affects millions, a breakthrough is on the horizon. 3Z Pharmaceuticals has unveiled a study that could change the landscape of ADHD treatment forever. This research highlights... |
| 17.02.2025 | 3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy | REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by ... |
| 17.02.2025 | 3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy | 3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy Mon, Feb 17, 2025 12:08 CET Report this content 3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a ... |
| 18.08.2023 | 3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling | REYKJAVIK, Iceland and BERLIN, Aug. 18, 2023 /PRNewswire/ -- Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug develop... |
| 22.11.2022 | 3Z: Zebrafish mutant model reveals novel drug candidates for ADHD | REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including... |
| 22.11.2022 | 3Z: Zebrafish mutant model reveals novel drug candidates for ADHD | REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including... |
| 21.11.2022 | Zebrafish mutant model reveals novel drug candidates for ADHD | Zebrafish mutant model reveals novel drug candidates for ADHD Mon, Nov 21, 2022 20:15 CET Report this content Reykjavik – 3Z. ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is b... |
Show more